Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Dr. Lachelle D. Weeks is a physician-scientist at Dana-Farber Cancer Institute in the Department of Medical Oncology, an Assistant Professor of Medicine at Harvard Medical School. She earned her MD and PhD degrees from Case Western Reserve University School of Medicine. Dr. Weeks subsequently completed her medical training at Brigham and Women’s Hospital Internal Medicine Residency and Dana-Farber Cancer Institute Hematology/Oncology Fellowship. Dr. Weeks is the director of the CHIP Clinic in the Dana-Farber Centers for Early Detection and Interception where she counsels patients who have clonal hematopoiesis, a precursor of blood cancers such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). As an independent investigator in the Division of Population Sciences, Dr. Weeks led the development of the clonal hematopoiesis risk score and her translational laboratory focuses on identifying risk factors for developing clonal hematopoiesis, understanding clinical and molecular features that predict risk of progression to overt malignancy, and designing therapeutic strategies to prevent adverse medical outcomes. She is the 2024-2027 Timmerman Traverse Clinical Investigator for the Damon Runyon Foundation for Cancer Research and a 2020 Harold Amos Medical Faculty Development Program recipient. Her work is also supported by funding from the Edward P. Evans Foundation for MDS, NHLBI, and Breakthrough Cancer.
0260: Development of a Consensus Definition of VEXAS Flare for Use in Clinical Research
Sunday, October 26, 2025
10:30 AM - 12:30 PM Central Time
Disclosure(s): Sobi: Advisor or Review Panel Member (Terminated, January 1, 2025), Consultant (Terminated, January 1, 2025); vertex: Consultant (Terminated, December 31, 2024)
